Costs of cardiovascular disease prevention care and scenarios for cost saving

Hendriks, Marleen Elisabeth; Bolarinwa, Oladimeji Akeem; Nelissen, Heleen E.; Boers, Alexander C.; Gomez, Gabriela B.; Tan, Siok Swan; Redekop, William K.; Adenusi, Peju; Lange, Joep M. A.; Agbede, Kayode; Akande, T.M.; Schultsz, Constance

doi:10.1097/hjh.0000000000000402

Cited by 21 publications

(39 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study demonstrated that implementation of CVD prevention care was feasible within a CBHI program. However, provision of high-quality care was resourceintense and involved considerable costs [12]. Rapid scaleup of CVD prevention care in SSA according to current WHO CVD prevention guidelines [2] may be too demanding, especially in settings where CBHI programs are not available.…”

Section: Insurance For Cardiovascular Disease Prevention In Nigeriamentioning

confidence: 99%

Feasibility and quality of cardiovascular disease prevention within a community-based health insurance program in rural Nigeria

Hendriks

Bolarinwa

Wit

et al. 2015

Journal of Hypertension

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Insurance For Cardiovascular Disease Prevention In Nigeriamentioning

confidence: 99%

Feasibility and quality of cardiovascular disease prevention within a community-based health insurance program in rural Nigeria

Hendriks

Bolarinwa

Wit

et al. 2015

Journal of Hypertension

Self Cite

View full text Add to dashboard Cite

show abstract

“…The authors of that study used a gross-costing method that was based on healthcare use and average per-unit cost data (17)(18)(19)(20)(21)(22). The cost of asthma-related hospitalizations, for example, was estimated by multiplying the number of asthma hospitalizations by the average cost for one hospitalization (7,23).…”

mentioning

confidence: 99%

The Economic Burden of Asthma in the United States, 2008–2013

2018

View full text Add to dashboard Cite

Rationale: Asthma is a chronic disease that affects quality of life, productivity at work and school, and healthcare use; and it can result in death. Measuring the current economic burden of asthma provides important information on the impact of asthma on society. This information can be used to make informed decisions about allocation of limited public health resources.Objectives: In this paper, we provide a comprehensive approach to estimating the current prevalence, medical costs, cost of absenteeism (missed work and school days), and mortality attributable to asthma from a national perspective. In addition, we estimate the association of the incremental medical cost of asthma with several important factors, including race/ethnicity, education, poverty, and insurance status. Methods:The primary source of data was the 2008-2013 household component of the Medical Expenditure Panel Survey. We defined treated asthma as the presence of at least one medical or pharmaceutical encounter or claim associated with asthma. For the main analysis, we applied two-part regression models to estimate asthma-related annual per-person incremental medical costs and negative binomial models to estimate absenteeism associated with asthma.Results: Of 213,994 people in the pooled sample, 10,237 persons had treated asthma (prevalence, 4.8%). The annual per-person incremental medical cost of asthma was $3,266 (in 2015 U.S. dollars), of which $1,830 was attributable to prescription medication, $640 to office visits, $529 to hospitalizations, $176 to hospitalbased outpatient visits, and $105 to emergency room visits. For certain groups, the per-person incremental medical cost of asthma differed from that of the population average, namely $2,145 for uninsured persons and $3,581 for those living below the poverty line. During 2008-2013, asthma was responsible for $3 billion in losses due to missed work and school days, $29 billion due to asthma-related mortality, and $50.3 billion in medical costs. All combined, the total cost of asthma in the United States based on the pooled sample amounted to $81.9 billion in 2013.Conclusions: Asthma places a significant economic burden on the United States, with a total cost of asthma, including costs incurred by absenteeism and mortality, of $81.9 billion in 2013. Author Contributions: T.N.: made substantial contributions to conception and design, acquisition of data, and analysis and interpretation of data; drafted the submitted article and revised it for important intellectual content; provided final approval of the version to be submitted for publication; and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; R.K.: made substantial contributions to the design and interpretation of data; revised the article for important intellectual content; made substantial contributions to the text of the drafts of the paper; and provided final approval of the version to be publishe...

show abstract

“…Looking through bibliographic sources, we found out that researchers from many countries had attempted to model some healthcare processes for the recent years. In particular, some of them suggested forming interdisciplinary teams and practicing systems approaches to chronic disease treatment [1,2,10,11], analyzing the incidence of chronic non-infectious diseases and risks of their occurrence [12][13][14]; frontend medical assistance [15] and vertical equality [16], optimization of planning, designing and financing of health systems in accordance with the number of † For the source article, please refer to: Куликова О.М., Усачева Е.В., Шамис В.А., Нелидова А.В., Боуш Г.Д. Модель финансового обеспечения регионального здравоохранения.…”

Section: Introductionmentioning

confidence: 99%

“…These models accommodate for sociopolitical circumstances and determinants of the health system [2,[17][18][19][20][21]; healthcare finance through the public-private partnership mechanism [22], spatial and time development of the health system [23][24][25]. The above studies involved correlation and regression analysis [13,17,19], Poisson lognormal mixed model in the Bayesian framework fitted to the INLA efficient estimation procedure [23], cost effectiveness estimation method [14], decision tree, Markov chain, micromodels, discrete and dynamic event modeling [24,26], descriptive statistics, forecasting and simulation [19-21, 24, 25], market research [10].…”

Section: Introductionmentioning

confidence: 99%

The Financing Model of the Regional Health System

Куликова¹,

Usacheva²,

Shamis³

et al. 2018

View full text Add to dashboard Cite

Subject The research devises the healthcare spending model in line with types and scope of medical aid, assesses indicators of the current and future planned periods. Objectives The research is an attempt to optimize healthcare spending by improving the way it is earmarked in line with the region's demand for certain types of medical aid and reallocating financial resources. Methods We use the conceptual modeling and Python 3. Results We devised the model to optimize expenditures in order to increment resources available for health care purposes by reallocating them in accordance with the analysis of the financial situation, classes of patients. Our model builds on the type of total medical expenditures on patients with certain diseases and adjustment of healthcare spending against the current year's plans.

show abstract

Costs of cardiovascular disease prevention care and scenarios for cost saving

Cited by 21 publications

References 41 publications

Feasibility and quality of cardiovascular disease prevention within a community-based health insurance program in rural Nigeria

Feasibility and quality of cardiovascular disease prevention within a community-based health insurance program in rural Nigeria

The Economic Burden of Asthma in the United States, 2008–2013

The Financing Model of the Regional Health System

Contact Info

Product

Resources

About